Navigation Links
Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Date:3/29/2009

Long-Term Data Demonstrate The OPTIMIZER(R) System to be Safe and Effective

ORLANDO, Fla., March 29 /PRNewswire/ -- Impulse Dynamics (U.S.A.) Inc. announced today findings from the FIX-HF-5 study of its OPTIMIZER System at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, Florida.

Previous studies have demonstrated safety and efficacy of the OPTIMIZER System's cardiac contractility modulation (CCM) signals when applied for three months. The FIX-HF-5 study was designed to test the longer term effects in the largest randomized study to date.

The study met its primary safety endpoint, which was a noninferiority demonstration of the composite of all-cause mortality and all-cause hospitalizations. In terms of efficacy, the results showed that, compared to the control group, patients treated with CCM signals over the other group had significantly improved exercise tolerance as judged by an increase in peak oxygen update (p=0.02) and an improvement in quality of life as judged by a reduction in the Minnesota Living with Heart Failure score (p<0.0001). Although the results did not meet the study's overall primary efficacy endpoint demonstrating improvement in ventilatory anaerobic threshold, it was met in a subgroup of the patients.

"We are pleased to report these longer term data that add to the growing wealth of knowledge showing the potential of CCM as a therapy for heart failure patients with no other options," said Dr. William Abraham, professor of internal medicine and director of the Division of Cardiovascular Medicine, Ohio State University Medical Center.

In a subgroup representing the "less sick" half of the study population (NYHA Class III with ejection fraction 25% and above), the study found even greater improvements not only in peak VO2 (p=0.001) and quality of life (p=0.003), but also in the primary endpoint of vent
'/>"/>

SOURCE Impulse Dynamics (U.S.A.) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
2. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
7. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
8. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
11. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... a privately held personalized medicine company focused on cancer, ... C (GCC) Lymph Nodes (LN) Classification as a Prognostic ... Pooled Analysis" at the 2012 American Society of Clinical ... 21, 2012.  The data from the paper demonstrate the ...
... 23, 2012 InspireMD, Inc. (OTC BB: NSPR) (the ... the development and commercialization of its proprietary stent platform ... today announced its business objectives for 2012 and reviewed ... the Company,s proprietary MicroNet™ platform technology. ...
Cached Medicine Technology:Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstageā„¢ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer 2InspireMD Provides Corporate Update, Plans for 2012 2InspireMD Provides Corporate Update, Plans for 2012 3InspireMD Provides Corporate Update, Plans for 2012 4InspireMD Provides Corporate Update, Plans for 2012 5InspireMD Provides Corporate Update, Plans for 2012 6
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... SXC Health Solutions, Inc.,("SXC" or the "Company") (NASDAQ: ... of,pharmacy benefits management services, announces that Mark Thierer,President ... Vice President,and Chief Financial Officer, will present at ... Grand Hyatt in New York City. SXC,s presentation,will ...
... Bermuda, Jan. 28 Warner Chilcott,Limited (Nasdaq: WCRX ) ... Total revenues for 2008 are expected to be in the ... driven by LOESTRIN 24 FE, DORYX,FEMCON FE, and TACLONEX. Gross ... be in the range of 80% to 81% in 2008., ...
... While many of today,s seniors are,retiring into what ... of life,they want to stay connected to the "real ... to trustworthy information and resources. In,addition, these adults are ... referrals for home repairs to coordinating personal,transportation and even ...
... NTY ), (http://www.NBTY.com ), a leading global manufacturer ... fiscal first quarter ended,December 31, 2007., For the ... were,$511 million compared to $506 million for the fiscal ... million or 1%., Net income for the fiscal ...
... Demo 08 -- Today, at DEMO 08,Acesis Inc. ... a,revolutionary on-demand electronic health record software solution. Acesis,Point-of-Care ... professionals by providing a secure, intuitive data capture,system ... "Acesis Point-of-Care is a striking example of ...
... 10 a.m. EST, January 28, 2008, WALTHAM, Mass., ... and Matria Healthcare, Inc. (Nasdaq: MATR ) today,announced ... to,which Inverness will acquire all outstanding shares of common ... cash plus $32.50 in,convertible preferred stock of Inverness (convertible ...
Cached Medicine News:Health News:SXC Health Solutions to present at the 2008 UBS Global Healthcare Services Conference 2Health News:Warner Chilcott Announces 2008 Financial Guidance 2Health News:Warner Chilcott Announces 2008 Financial Guidance 3Health News:Warner Chilcott Announces 2008 Financial Guidance 4Health News:Warner Chilcott Announces 2008 Financial Guidance 5Health News:Senior Citizens Bureau Empowers Today's Seniors: National Non-profit Serves as Community Resource for Seniors, Their Children, Caregivers and Even Advocates 2Health News:Senior Citizens Bureau Empowers Today's Seniors: National Non-profit Serves as Community Resource for Seniors, Their Children, Caregivers and Even Advocates 3Health News:NBTY Reports First Quarter Results 2Health News:NBTY Reports First Quarter Results 3Health News:NBTY Reports First Quarter Results 4Health News:NBTY Reports First Quarter Results 5Health News:NBTY Reports First Quarter Results 6Health News:NBTY Reports First Quarter Results 7Health News:NBTY Reports First Quarter Results 8Health News:NBTY Reports First Quarter Results 9Health News:NBTY Reports First Quarter Results 10Health News:NBTY Reports First Quarter Results 11Health News:NBTY Reports First Quarter Results 12Health News:NBTY Reports First Quarter Results 13Health News:NBTY Reports First Quarter Results 14Health News:Acesis Point-of-Care, The Physician's Ultimate Replacement for Pen and Paper, Unveiled at DEMO 08 2Health News:Acesis Point-of-Care, The Physician's Ultimate Replacement for Pen and Paper, Unveiled at DEMO 08 3Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 2Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 3Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 4Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 5Health News:Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc. 6
... higher magnification and increased stereopsis, the Central ... visualization to the equatorial regions. The Central ... and in membrane peeling in proliferative vitreoretinopathy ... Lenses The ACS Vitrectomy Lenses from Volk ...
... the high resolution, high magnification and field ... simple two part design separates for easy ... Simply autoclave, add saline or water to ... use. (ACS) AutoClave Sterilizable Lenses The ACS ...
... These patented ACS lenses offer the ... view as the original clariVits. The simple ... while maintaining its integrity during surgery. Simply ... contact element, then lock together for use. ...
... over a wide field ... entire retina, detailed retinal ... tears, diagnosis and treatment ... the vitreous cavity is ...
Medicine Products: